Dr Brendon Neuen
MBBS(Hons I) MSc(Oxon)
Dr Brendon Neuen is an academic nephrology fellow and NHMRC Postgraduate Scholar at The George Institute for Global Health Australia. He graduated in medicine at James Cook University with 1st Class Honours and an Academic Medal and holds a Masters in Global Health and Epidemiology from the University of Oxford, where he was fully funded by a Clarendon Scholarship and received the prize for the top ranked dissertation.
He is an internationally recognised expert on the efficacy and safety of SGLT2 inhibitors in people with diabetes and chronic kidney disease, having led several analyses of the landmark CANVAS and CREDENCE trials. He is involved in several ongoing international multi-centre randomized trials and has published over 60 peer-reviewed articles in general medical journals including The Lancet, BMJ and Annals of Internal Medicine, and specialty journals including Lancet Diabetes and Endocrinology, Circulation, and the Journal of the American Society of Nephrology. In addition, he provides strategic direction on research and education by serving on boards or committees of the Australasian Kidney Trials Network, Australian and New Zealand Society of Nephrology, and the International Society of Nephrology.
His work has directly informed more than a dozen major international clinical practice guidelines, position papers and scientific statements which define best practice for the care of people with type 2 diabetes and kidney disease, including the Kidney Disease Improving Global Outcomes (KDIGO) Guidelines and the American Diabetes Association (ADA) Standards of Care.